^
Association details:
Biomarker:EGFR D761Y
Cancer:Lung Adenocarcinoma
Drug:gefitinib (EGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

Excerpt:
In patients whose lung adenocarcinomas harbor epidermal growth factor receptor (EGFR) tyrosine kinase domain mutations, acquired resistance to the tyrosine kinase inhibitors (TKI) gefitinib (Iressa) and erlotinib (Tarceva)....EGFR mutants containing the D761Y amino acid change are less sensitive to inhibition by EGFR TKIs.
DOI:
10.1158/1078-0432.CCR-06-1570